目的 探究通心絡(luò)膠囊聯(lián)合艾司洛爾治療冠心病心肌缺血的臨床療效。方法 選取保定市252醫(yī)院2012年10月—2015年10月收治的冠心病心肌缺血患者100例，隨機(jī)分為對(duì)照組（50例）和治療組（50例）。兩組均給予基礎(chǔ)治療，對(duì)照組iv鹽酸艾司洛爾注射液，負(fù)荷量0.5 mg/(kg·min)，持續(xù)1 min。隨后靜脈點(diǎn)滴維持量0.05 mg/(kg·min)，4 min后若療效理想則繼續(xù)維持，若療效不佳可重復(fù)給予負(fù)荷量并維持量以0.05 mg/(kg·min)的幅度遞增。治療組在對(duì)照組的基礎(chǔ)上口服通心絡(luò)膠囊，3粒/次，3次/d，兩組均連續(xù)治療2周。治療后，比較兩組的臨床療效、心率、血壓和血脂的變化情況。結(jié)果 治療后，對(duì)照組和治療組總有效率分別為84.00%和94.00%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組的心率、血壓和血脂明顯降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些指標(biāo)的下降幅度優(yōu)于對(duì)照組，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 通心絡(luò)膠囊聯(lián)合艾司洛爾治療冠心病心肌缺血具有較好的臨床療效，可明顯改善患者的心率、血壓和血脂，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To explore the clinical effect of Tongxinluo Capsules combined with esmolol in treatment of coronary heart disease with myocardial ischemia. Methods Patients (100 cases) with coronary heart disease with myocardial ischemia in No. 252 Hospital of Baoding from October 2012 to October 2015 were randomly divided into control (50 cases) and treatment (50 cases) groups. All patients were given basic treatment. Patients in the control group were iv administered with Esmolol Hydrochloride Injection, with the load of 0.5 mg/(kg·min) continuing for 1 min. Then they were administered with Esmolol Hydrochloride Injection for iv drip, maintained the dosage of 0.05 mg/(kg·min). After 4 min, maintain the dosage if the clinical efficacy was ideal, or give the load of 0.5 mg/(kg·min) repeatedly and gradually added the maintained dosage at the amplitude of 0.05 mg/(kg·min). The patients in the treatment group were po administered with Tongxinluo Capsules on the basis of control group, 3 grains/time, three times daily. The patients in two groups were treated for 2 weeks. After treatment, the clinical efficacy, changes of heart rate, blood pressure, and blood lipid in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment group were 84.00% and 94.00%, respectively, and there were differences between two groups (P<0.05). After treatment, heart rate, blood pressure, and blood lipid in two groups were lower than those before treatment with significant difference (P<0.05). And these indexes in the treatment group were lower than those in the control group, and the difference was significant (P<0.05). Conclusion Tongxinluo Capsules combined with esmolol has clinical curative effect in treatment of coronary heart disease with myocardial ischemia, and can significantly improve the heart rate, blood pressure, and blood lipid, which has a certain clinical application.